Parohia “Sf. Nectarie Taumaturgul” – Coslada (Madrid)

Parroquia “San Nectario el Taumaturgo”–Coslada/Romanian Orthodox Parish "St. Nectarios, the Healer"-Coslada

Archive for august 10th, 2009

Fast-tracked Swine Flu Vaccine under Fire

The vaccines far more deadly than the swine flu; mass vaccinations a recipe for disaster Dr. Mae-Wan Ho and Prof. Joe Cummins

This report has been submitted to Sir Liam Donaldson, Chief Medical Officer of the UK, and to the US Food and Drugs Administration

Please circulate widely, with all the hyperlinks included, to your elected representatives, wherever you are

A swine flu outbreak occurred in Mexico and the United States in April 2009 and spread rapidly around the world by human-to human transmission. The new type A H1N1 influenza virus is unlike any that had been previously isolated [1, 2], judging from the first data released in May. It is a messy combination of sequences from bird, human and swine flu virus lineages from North America and Eurasia. A senior virologist based in Canberra, Australia, told the press he thought that the virus could have been created in the laboratory and released by accident [3]. Some even suggest it was made intentionally as a bioweapon [4], while others blame the intensive livestock industry and extensive trafficking of love animals over long distances, which provide plenty of opportunity for generating exotic recombinants [5]. But what worries the public most is the mass vaccination programmes governments are putting in place to combat the emerging pandemic, which could well be worse than the pandemic itself.

Watchdog opposes fast-track vaccine for school children

The US government is intending to vaccinate all children in September when school re-opens, and the country’s vaccine watchdog National Vaccine Information Center (NVIC)  has called on the Obama Administration and all state Governors to provide evidence that the move is [6] “necessary and safe”, demanding “strong mechanisms for vaccine safety screening, recording, monitoring, reporting and vaccine injury compensation.”

The US Departments of Health and Homeland Security had declared a national public health emergency in April soon after the swine flu outbreak. As a result, some schools were closed, people quarantined, and drug companies were given contracts worth $7billon to make vaccines that are being fast tracked by the Food and Drugs Administration [7]. That means they will only be tested for a few weeks on several hundred children and adult volunteers before being given to all school children this fall.

Furthermore, under federal legislation passed by Congress since 2001, an Emergency Use Authorization allows drug companies, health officials and anyone administering experimental vaccines to Americans during a declared public health emergency to be protected from liability if people get injured. US Secretary of Health and Human Services Kathleen Sebelius has granted vaccine makers total legal immunity from any lawsuits that may result from any new swine flu vaccine. And some states may make the vaccination mandatory by law.

The NVIC is asking whether the states are prepared to obey vaccine safety provisions in the 1986 National Childhood Vaccine Injury Act, which include: 1. Giving parents written information about vaccine benefits and risks before children are vaccinated; 2. Keeping a record of which vaccines the children get, including the manufacturer’s name and lot number; 3. Recording which vaccines were given in the child’s medical record; and 4. Recording serious health problems that develop after vaccination in the child’s medical record and immediately making a report to the federal Vaccine Adverse Event Reporting System.

NVIC also wants to know if the states are prepared to provide financial compensation to children injured by the swine flu vaccines, whether parents will be given “complete, truthful information about swine flu vaccine risks”, and have the right to say “no” to vaccination.

Co-founder and president of NVIC Barbara Loe Fisher said [6]: “Parents and legislators should be asking themselves right now: Why are children the first to get experimental swine flu vaccines? Are schools equipped to get signed informed consent from parents before vaccination, keep accurate vaccination records and screen out children biologically at high risk for suffering vaccine reactions? Will people giving these vaccines know how to monitor children afterwards and immediately record, report and treat serious health problems that develop? And will states have the financial resources to compensate children who are injured?”

WHO and mass vaccination fever

The mass vaccination order has come from the World Health Organization (WHO) [8].  In early July 2009, a group of vaccination experts concluded that the pandemic is unstoppable, and Marie-Paul Kieny, WHO director on vaccine research said all nations will need access to vaccines, and that a vaccine should be available as early as September.

Critics point out that the ‘vaccination experts’ are dominated by the vaccine makers standing to gain from the enormously lucrative vaccine and antiviral contracts awarded by governments. But the decisive argument against mass vaccinations is that flu shots simply don’t work and are dangerous [9].

Flu shots ineffective and increase risks of asthma

There are widely acknowledged reasons why flu vaccines won’t work, as already pointed out with regard to the much touted vaccines against the ‘pandemic bird flu’ that has yet to materialize [10] (How to Stop Bird Flu Instead, SiS 35). The flu virus changes quickly – even without the help of genetic engineering in the laboratory, and especially with the help of the intensive livestock industry – whereas the vaccines target specific strains. Furthermore, flu vaccination does not give permanent protection, and must be repeated annually; the vaccines are difficult to mass-produce, and some strains won’t grow at all under laboratory conditions.

Numerous studies have documented that flu shots give little or no protection against infection and illness, and there is no reason to believe that swine flu vaccines will be different.

A review of 51 separate studies involving more than 294 000 children found that in children aged from two years, nasal spray vaccines made from weakened influenza viruses and injected vaccines made from the killed virus prevented 82 and 59 percent of illnesses. The prevention of ‘flu-like illness’ caused by other types of viruses was only 33 and 36 percent respectively. In children under the age of two, the efficacy of inactivated vaccine was similar to placebo. It was not possible to analyse the safety of vaccines from the studies due to the lack of information, and lack of standardization on the little information available [11]. A report published in 2008 found flu vaccines in young children made no difference in the number of flu-related doctor and hospital visits [12].

On the other hand, a study of 800 children with asthma found that those receiving a flu vaccine had a significantly increased risk of asthma-related doctor and emergency room visits [13]; the odds ratios were 3.4 and 1.9 respectively. This was confirmed in a report published in 2009, which showed children with asthma who received FluMist had a 3-fold increased risk of hospitalization [14]

Flu vaccines are equally useless for adults, including the elderly, giving little or no protection against infection or illnesses including pneumonia (see [9]).

Toxic adjuvants in flu vaccines

Vaccines themselves can be dangerous, especially live, attenuated viral vaccines or the new recombinant nucleic acid vaccines [10], they have the potential to generate virulent viruses by recombination and the recombinant nucleic acids could cause autoimmune diseases.

A further major source of toxicity in the case of the flu vaccines are the adjuvants, substances added in order to boost the immunogenicity of the vaccines. There is a large literature on the toxicities of adjuvants.  Most flu vaccines contain dangerous levels of mercury in the form of thimerosal, a deadly preservative 50 times more toxic than mercury itself [9]. At high enough doses, it can cause long-term immune, sensory, neurological, motor, and behavioural dysfunctions. Also associated with mercury poisoning are autism, attention deficit disorder, multiple sclerosis, and speech and language deficiencies. The Institute of Medicine has warned that infants, children, and pregnant women should not be injected with thimerosal, yet the majority of flu shots contain 25 micrograms of it.

Another common adjuvant is alum or aluminium hydroxide, which can cause vaccine allergy, anaphylaxis, and macrophage myofascitis, a chronic inflammation syndrome, In cats, alum also gives rise to fibrosarcomas at the site of injection [15]. Numerous new adjuvants are no better, and could be worse. According to a recent review in a science and business pharmaceutical publication [15], most newer adjuvants including MF59, ISCOMS, QS21, AS02, and AS04 have “substantially higher local reactogenicity and systemic toxicity than alum.”

Current status of swine flu vaccines

Five different companies have been contracted to produce vaccines worldwide: Baxter International, GlaxoSmithKline, Novartis and Sanofi-Aventis and AstroZeneca [16]. Already stretched beyond capacity, there is every intention to make smaller vaccine doses go further with a range of new adjuvants [17], with the blessing of the WHO (see later).

Flu vaccines are traditionally produced from non-virulent (attenuated or weakened) influenza viruses (see Box for a description of the viruses). To be effective, the genes of the non- virulent virus used must match those of the viral strain spreading in the population. Activation of the immune system by exposure to the non pathogenic form of the circulating pathogenic strain leads to the production of antibodies that will confer protection against the pathogenic strain. Producing the non-virulent virus involves first identifying and then recreating the subtypes of two of the virus’s surface proteins, haemagglutinin (H) and neuraminidase (N), which determine the strain’s virulence and ability to spread, and are also the target proteins for vaccine production.

Influenza virusesThere are 3 types of influenza viruses, A, B and C. The influenza A type virus is the main one that cause diseases in birds and mammals. Its genome consists of 8 segments of RNA coding for 11 proteins, and the viruses are further classified by subtype on the basis of the two main surface glycoproteins (proteins with complex carbohydrate side chains): haemagglutinin (H) and neuraminidase (N) [18]. The segmented genome enables the virus to’ reassort’ (shuffle) segments as well as recombine within segments, thereby greatly increasing the rate of evolution and generation of new strains. Reassortment is also widely exploited in the laboratory in the process of creating vaccine strains. To-date, 16 H and 9 N subtypes have been detected in numerous combinations circulating in wild birds [19].

Seed viruses are first made to provide the starting material for large scale production of live non-virulent flu viruses. The seed viruses are approved by the WHO or the United States Food and Drug Administration (USFDA). The usual method of seed virus production is reassortment (see Box). Fertilized chicken eggs are injected with both a standard non-pathogenic influenza strain known to grow well in eggs and the strain that carries the genes expressing the desired vaccine H and N protein subtypes. The two viruses multiply, and their eight genome segments reassort with 256 possible combinations. The resulting recombinant viruses are then screened for the desired virus with the six genome segments that allow the standard strain to grow so well in eggs and the H and N genes from the circulating strain. The seed virus is then injected into millions of eggs for mass production of vaccine. This conventional method of seed stock production takes about one to two months to complete [20].

Cell culture systems may eventually replace chicken eggs. Baxter International applied for a patent on a process using cell culture to produce quantities of infecting virus, which are harvested, inactivated with formaldehyde and ultraviolet light, and then detergent [21].  Baxter has produced H5N1 whole virus vaccines in a Vero cell line derived from the kidney of an African green monkey, and conducted phase 1 and 2 clinical trials with and without aluminium hydroxide as adjuvant [22, 23]. The main finding was that the toxic adjuvant did not increase neutralising antibodies against the vaccine strain. Baxter has agreed to ship H1N1 vaccine by the end of July or early August 2009 but details of the production of that vaccine have not yet been released to the public [16].

In December, a Baxter facility in Austria sent a human flu vaccine contaminated with the deadly H5N1 live avian flu virus to 18 countries, including the Czech Republic, where testing showed it killed the ferrets inoculated [24].  Czech newspapers questioned whether Baxter was involved in a deliberate attempt to start a pandemic.

Norvatis, another big pharma, announced on 13 June that it, too, has produced a swine flu vaccine using cell-based technology and the proprietary adjuvant MF59®. The MF59® adjuvant is oil based and contains Tween80, Span85, and squalene [25]. In studies of oil-based adjuvants in rats, the animals were rendered crippled and paralyzed. Squalene brought on severe arthritis symptoms in rats, and studies in humans given from 10 to 20 ppb (parts per billion) of squalene showed severe immune system impact and development of autoimmune disorders [26].

Novartis was in the news in 2008 for a clinical trial of a H5N1 vaccine in Poland. The trial was administered by local nurses and doctors who gave the vaccine to 350 homeless people, leaving 21 died; and were prosecuted by the Polish police [27, 28]. Novartis claimed the deaths were unrelated to the H5N1 vaccine [29], which had been “tested on 3500 other people without any deaths.”

GlaxoSmithKline’s vaccine will be made up of antigens of the recently isolated influenza strain, and also contains its own proprietary adjuvant system AS03 that has been approved in the EU along with its H5N1 bird flu vaccine in 2008. According to the European Public Assessment Report [30], AS03 adjuvant is composed of squalene (10.68 milligrams), DL-α-tocopherol (11.86 milligrams) and polysorbate 80 (4.85 milligrams). The H5N1 vaccine also contains 5 micrograms thiomersal, as well as Polysorbate 80, Octoxynol 10, and various inorganic salts. The company is aggressively promoting various adjuvant systems as its ‘adjuvant advantage’ that reduces the dose of vaccines [31].

A recent WHO survey of primary vaccine producers concluded that the potential output of 4.9 Billion doses of H1N1 vaccine per year is a best-case scenario, assuming among other factors that the most dose-sparing formulation (that will include toxic adjuvants) be selected by each manufacturer and that production will take place at full capacity. WHO Director-General, Dr .Margaret Chan,  and the United Nations Secretary-General, Mr Ban Ki-moon, met with senior officials of vaccine manufacturers on 19 May and asked  them to reserve part of their production capacity for poor countries that would otherwise have no or little access to vaccine in the case of a pandemic [32].

The last mass-vaccination in the US was a disaster. In 1976, cases of swine flu were found in soldiers at Fort Dix, New Jersey, and one of them died, most likely of physical overexertion rather than from the infection [7]. This led to the launch of a mass vaccination of 40 million against a pandemic that never materialized. Thousands filed claims for injury. At least 25 died and 500 developed paralyzing Guillain-Barre syndrome [33, 34].

Swine flu syndromes mostly mild

As of 22 July 2009, the CDC listed a total of 40 617 cases in the US, with 319 fatalities, giving a fatalites/case ratio of 0.8 percent [35]; though the real death rate – among all cases of infection including the mild ones that go unreported – is probably much lower. Experts estimate that only 1 out of 20 cases are reported [36].

The UK is the worst affected European country, and the pandemic is in the headlines everyday in July. A new telephone helpline was set up on 23 July to let people get advice and tamiflu without seeing a doctor. In that week, there has been a record rise in cases to 100 000 and a total of 30 deaths so far [37], giving a fatalities/case ratio of 0.03 percent, a more accurate reflection of the actual death rate.

UK’s chief medical officer Sir Liam Donaldson has ordered the NHS to plan for as many as 65 000 deaths, with 350 a day at the peak [38]. There has been no plan as yet for mass vaccination; but the UK government has advance orders for 195 million doses of vaccine with GlaxoSmithKline (GSK).

The vaccine that GSK is developing will be tested on a limited number of people as the UK drug company reportedly [39] “weighs the pandemic danger against the risks of an unsafe shot.” This was criticized as “risky” by Prof. Hugh Pennington, a retired microbiologist at the University of Aberdeen, Scotland. “By limiting clinical trials, Glaxo raises the danger that the vaccine dose isn’t properly calibrated, and could lead to shots that don’t protect people from the virus or at worse are unsafe,” Pennington said.

Pennington added that the shot’s ability to trigger the body’s defences is crucial and requires tests to determine the best dose and whether an adjuvant is needed to bolster the immunity. (As we know, GSK is definitely promoting its new range of toxic adjuvants.) He also referred to the Fort Dix incident in 1976 (see earlier).

France has ordered vaccines from Sanofi, GSK and Novartis, but sees no reason to ask vaccine makers to shorten or skip clinical trials [16]. Sanofi-Aventis, the French drug maker developing its own swine flu vaccine will begin testing the product in early August, and estimates it will need as much as two and a half months of tests before having a shot that’s “both safe and protective”, according to Albert Garcia, speaking for the company’s vaccine unit, “the vaccine will be ready in November or December, he said.

Baxter, however, will produce a vaccine by early August for clinical tests.

Glaxo also said it is developing a face mask coated with antivirals to prevent infection and boosting production of its Relenza drug for patients already suffering from swine flu.

There are obviously safer and more effective ways to combat the pandemic than mass vaccinations: washing hands often, sneezing into a tissue that can be safely disposed of, avoiding unnecessary gatherings, and delay opening schools – all advised by governments – and we would add, eating healthily, exercise, and getting enough vitamin D to boost your natural immunity [10].

References

1. New details on virus’s promiscuous past”, Jon Cohen, Science 2009, 324, 1127.

2. Garten RJ, Davis CT,Tussell CA et al.  Antigenic and genetic charaatcteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 2009, 325, 197-201.

3. Virologist to make his case for lab origin of swine flu”, Peter Duveen, Opednews.com, 4 July 2009, http://www.opednews.com/articles/Virologist-to-make-his-cas-by-Peter-Duveen-090630-103.html

4. Is swine flu a biological weapon?”, Paul Joseph Watson, PrisonPlanet.com 27 April 2009, http://www.prisonplanet.com/is-swine-flu-a-biological-weapon.htm

5. CDC confirms ties to virus first discovered in U.S. pig factories” Michael Greger, 3 May 2009, http://www.hsus.org/farm/news/ournews/swine_flu_virus_origin_1998_042909.html

6. “Swine flu vaccine should not be given to children in schools”, Barbara Loe Fisher, National Vaccine Information Center, 22 July 2009,
http://www.nvic.org/NVIC-Vaccine-News/July-2009/Swine-Flu-Vaccine-Should-Not-Be-Given-to-Children.aspx

7. “Now legal immunity for swine flu vaccine makers” F, William Engdahl,  Global Research 20 July 2009, http://www.globalresearch.ca/index.php?context=va&aid=14453

8. Swine flu pandemic now ‘unstoppable’: WHO official”, Agence France-Presse 13 July 2009, Calgary Herald, http://www.calgaryherald.com/Swine+pandemic+unstoppable+official/1788693/story.html

9. What are the dangers of mandatory swine flu vaccination? Dr. Mercola, June 2009, http://blogs.mercola.com/sites/vitalvotes/archive/2009/07/15/What-are-the-Dangers-of-Mandatory
Mandatory-Swine-Flu-Vaccination.aspx

10. Ho MW. How to stop bir flu instead of the vaccine-antiviral model. Science in Society 35. 40-42, 2007.

11. Jefferson T, Rivett A, Harnden A, DiPietrantoni C, and Demicheli V. Vaccines for preventing influenza in healthy children (Review). Cochrane Database Systematic Review 23 April 2009, http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004879/pdf_fs.html

12. Szilagyi PG, Fairbrother G, Griffin MR et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med 2008, 162, 943-51. http://www.ncbi.nlm.nih.gov/pubmed/18838647

13. Christy C, Aligne C, Auinger P, Pulcino T and Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch. Dis Child 2004, 89, 734-5, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=15269071

14. Flu vaccination may triple risk for flu-related hospitalization in children with asthma, 25 May 2009, http://www.medscape.com/viewarticle/703235

15. Petrovsky N, Heinzel S, Honda Y, Lyons AB. New-age vaccine adjuvants, friend or foe? BioPharm International 2 August 2007, http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=444996&sk=&date=&pageID=5

16.  “Update: 1-Baxter can take no more H1N1 flu vaccine orders”, Bill Berkerto, 16 July 2009, Reuters.  http://www.reuters.com/article/marketsnews/idINN1644290820090716?rpc=33

17. H1N1 ‘swine flu’ vaccine, postnote, May 2009, number 331, http://www.parliament.uk/documents/upload/postpn331.pdf

18. Avian Influenza (Bird Flu) CDC, 18 November 2005, http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm

19. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME and Fouchier RAM. Global patterns of influenza A virus in wild birds. Science 2006, 312, 384-8.

20. Hood E. Environews Innovations 2006 Environmental Health Perpectives 114,A108-111.

21. Kistner,O,Tauer,C, Barrett,N. Mundt,W. Method for Producing Viral Vaccines  2009 Patent application  US2009/0060950A1

22. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008 Jun 12;358(24):2573-84.

23. Ketel.W,Dekker,C,Mink,C,Campbell,J,Edwards,K,Patel,S,Ho,D,Talbot,H,Guo,K,Noah,D,Hill,H.Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults Vaccine 2009 in press doi:10.1016/j.vaccine.2009.03.015

24.  “Bird flu mix-up could have spelled disaster”, NewScientist 6 March 2009, http://www.newscientist.com/article/mg20126983.400

25. Kenney RT and Edelman R. Survey of human-use adjuvants. Expert Review of Vaccines April 2003; 2(2):167-88, http://www.ncbi.nlm.nih.gov/pubmed/12899569?ordinalpos=5&itool=EntrezSystem2.PEntrez.
Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum

26. “Vaccines may be linked to Gulf War Syndrome”, Chiroweb.com, June 12, 2000, http://www.chiroweb.com/mpacms/dc/article.php?id=31730

27. “Homeless people die after bird flu vaccine trial in Poland”, Mathew Day, Telegraph, 2 July 2008, http://www.telegraph.co.uk/news/worldnews/europe/poland/2235676/Homeless-people-
die-after-bird-flu-vaccine-trial-in-Poland.html

28. “Homeless people die after trials of bird-flu vaccine”, 10 July 2008, Pharmaceutical Portal for Poland, http://www.pharmapoland.com/next.php?id=62409

29. “Polish industry not dented by deaths”, Emma Dorey, Entrepreneur, 21 July 2008, http://www.entrepreneur.com/tradejournals/article/181991358.html

30. Pandermrix = European Public Assessment Report [EMEA] 27 September 2009, http://www.emea.europa.eu/humandocs/Humans/EPAR/pandemrix/pandemrix.htm

31. Vaccine adjuvant system technology background information. GlaxoSmithKline, accessed 25 July 2009, http://www.gsk.com/media/flu/flu-adjuvant.pdf

32. Collin N, de Radiguès X, Kieny MP; the World Health Organization H1N1 Vaccine Task Force.New influenza A(H1N1) vaccine: How ready are we for large-scale production? Vaccine. 2009 Jun 26 in press doi:10.1016/j.vaccine.2009.06.034

33. 1976 swine flu outbreak, Wikipedia, 22 July 2009, http://en.wikipedia.org/wiki/1976_swine_flu_outbreak

34. Haber P, Sejvar J, Mikaeloff Y and DeStefano F. Vaccine and Guilaain-Barre syndrome. Drug Saf 2009, 32, 309-23.

35. 2009 flu pandemic in the United States”, Wikipdeia, 22 July 2009, http://en.wikipedia.org/wiki/2009_flu_pandemic_in_the_United_States

36. 2009 flu pandemic, Wikipedia, http://en.wikipedia.org/wiki/2009_flu_pandemic

37. “Swine flu website overwhelmed by demand as new cases double in a week”, Owen Bowcott and Severin Carrell, The Guardian, 23 July 2009, http://www.guardian.co.uk/world/2009/jul/23/swine-flu-website-overwhelmed

38. “Swine flu: medical chief orders NHS to prepare for 65 000 deaths – with a toll of as many as 350 a day”, Daniel Martin, The Daily Mail, 17 July 2009,  T, http://www.dailymail.co.uk/news/article-1200012/Swine-flu-Every-child-16-vaccinated–when.html

39.  “Glaxo to limit tests of flu vaccine, citing urgency”, Jason Gale and Trista Kelley, Bloomberg Press, 22 July 2009, http://www.bloomberg.com/apps/news?pid=20601102&sid=apkg_4J.PCEw

From : www.i-sis.org.uk

STUDIU STIINTIFIC ASUPRA PERICULOZITATII VACCINULUI GRIPEI PORCINE

swineflu1_1394571c.jpg

Vaccinul e mai periculos decit virusul. Vaccinarea in masa: reteta pentru dezastru

de Dr. Mae-Wan Ho si Prof. Joe Cummins

Traducere dupa: http://www.i-sis.org.uk/fastTrackSwineFluVaccineUnderFire.php

“Acest raport a fost trimis catre Sir Liam Donaldson (Chief Medical Officer, UK) si Administratiei SUA pentru Hrana si Medicamente.Va rugam asigurati transmiterea pe scara larga a acestui material. Gripa porcina a aparut in Mexico si SUA in aprilie 2009 si s-a raspindit pe tot globul prin transmisie de la om la om. Noul tip de virus gripa A H1N1 nu se aseamana cu nici un alt virus precedent izolat (1,2), dupa cum arata primele date eliberate in mai. Este o combinatie ciudata de secvente (de material genetic, n.tr.) provenite de la virusii de gripa aviara, umana si porcina din America de Nord si Eurasia.Un virologist din Canberra, Australia a declarat presei ca exista posibilitatea ca virusul sa fi fost creat in laborator si pus in libertate din greseala (3). Unii au sugerat ca ar putea fi fost creat pe post de arma biologica (4), in timp ce altii dau vina pe industria zootehnica intensiva si pe traficul extins al animalelor de companie, care creeaza oportunitatea aparitiei unor virusi recombinati (5).Dar ceea ce ingrijoreaza mai ales publicul sunt  programele guvernamentale de vaccinare in masa menite sa combata epidemia si care ar putea fi mai rele decit epidemia insasi.

2847401147-chinese-firm-begins-swine-flu-vaccine-trial-state-media.jpg

Centrul de supraveghere se opune vaccinarii şcolarilor

Guvernul SUA intentioneaza ca in momentul redeschiderii scolilor, in septembrie, sa vaccineze toti elevii, dar Centrul National de Informare asupra Vaccinurilor (CNIV) a cerut administratiei Obama si tuturor guvernatorilor de stat sa aduca dovezi ca aceasta este (6) “necesar si fara riscuri de sanatate” cerand “controlul strict al vaccinului, inregistrarea, monitorizarea, raportarea si asigurarea de compensatii in cazul tulburarilor produse de vaccinare”.Departamentul de Sanatate al SUA si cel al Securitatii Nationale au declarat in aprilie, la scurt timp dupa aparitia epidemiei, ca gripa porcina este o urgenta a sanatatii nationale. Ca rezultat unele scoli au fost inchise, unii oameni pusi in carantina iar companiile farmaceutice au incheiat contracte valorind in total 7 miliarde dolari pentru a fabrica vaccinuri care sunt vor fi puse accelerat in circulatie de catre Administratia pentru Alimente si Medicamente (7).numai citeva saptamini pe citeva sute de voluntari, copii si adulti, inainte de a fi administrate tuturor scolarilor, in toamna.Mai mult, ca urmare a legislatiei federale adoptate de Congres in 2001, o autorizatie pentru uz de urgenta permite companiilor farmaceutice, oficialitatilor din sistemul de sanatate si oricui care se ocupa de administrarea vaccinurilor experimentale, ca in timpul unei stari de urgenta, sa fie protejat legal in cazul in care populatia sufera leziuni in urma vaccinarii. Secretarul Serviciilor Umane si de Sanatate, Kathleen Sebelius, a garantat fabricantilor de vaccinuri imunitate totala in fata legii, impotriva oricaror plingeri in instanta care ar putea rezulta in urma vaccinarii. Unele state vor sa impuna vaccinarea obligatoriu prin lege.CNIV se intreaba daca statele sunt pregatite sa se supuna reglementarilor de securitate ale vaccinurilor din 1986, cuprinse in Actul National despre Leziunile rezultate din Vaccinarea Infantila, care include: Aceasta inseamna ca vaccinurile vor fi testate pentru

  • Sa se dea parintilor informatii scrise despre beneficiile si riscurile vaccinului inaintea vaccinarii copilului
  • Inregistrarea vaccinurilor administrate copilului inclusiv numele producatorului si numarul lotului
  • Inregistrarea vaccinurilor administrate in cartea de sanatate a copilului
  • Inregistrarea problemelor de sanatate seriose aparute ca rezultat al vaccinarii in cartea de sanatate a copilului si inaintarea imediata a unui raport Sistemului de Raportare a Reactiilor Adverse ale Vaccinarilor

CNIV ar vrea sa stie daca statul va acorda compensatii finaciare pentru eventuala lezare a copiilor prin vaccinare impotriva gripei porcine si daca parintilor li se vor da “informatii complete si reale despre riscurile vacinarii impotriva virusului gripei porcine” si daca vor avea dreptul sa zica “nu” vaccinarii.Co-fondatorul si presedintele CNIV Barbara Loe Fisher a spus (6):

Parintii si legislatorii ar trebui sa se intrebe:

  • De ce sunt copiii cei care trebuie sa primeasca cei dintii un vaccin experimental?
  • Sunt scolile echipate ca sa inregistreze consensul informat al parintilor inainte de vaccinare, sa tina evidenta vaccinarilor si sa excepteze de la vaccinare copii care din motive de sanatate ar fi supusi unor riscuri majore in cazul vaccinarii?
  • Vor sti cei care administreaza vaccinul sa monitorizeze copii, sa inregistreze imediat, sa raporteze si sa trateze orice problema de sanatate seriosa aparuta in urma vaccinarii?
  • Va avea statul resurse financiare pentru a acorda compensatii copiilor lezati?

swine-flu-vaccine-months-away-7038016300.jpg

OMS si febra vaccinarii in masa

Ordinul vaccinarii in masa a venit de la OMS (8). La inceputul lui iulie 2009, un grup de experti in vaccinuri a concluzionat ca epidemia e de neoprit iar Marie-Paul Kieny, directorul OMS pe directia cercetarii vaccinurilor, a spus ca toate natiunile vor trebui sa aiba acces la vaccinuri si ca vaccinul va trebui sa fie gata de administrare in septembrie.Criticii arata ca „expertii in vaccinare” sunt influentati de producatorii de vaccinuri care vor sa cistige profituri enorme de pe urma contractelor cu guvernele. Dar argumentul decisiv impotriva vaccinarii in masa e ca vaccinul nu e eficient ba, mai mult, e chiar periculos.

mercury-in-the-vaccines.jpg

Vaccinul impotriva gripei porcine e ineficient si creste riscul de astm

Exista numeroase argumente care arata ca vaccinurile impotriva gripei nu functioneaza dupa cum s-a si aratat in privinta celebrului vaccin impotriva pandemiei de gripa aviara, care vaccin inca nu a fost produs.Numeroase studii arata ca vaccinurile anti-gripale protejeaza putin sau deloc si nu exista motive sa credem ca vaccinul impotriva gripei porcine va fi diferit. O revizie a 51 de studii separate implicind peste 294 000 copii au aratat ca la copii peste 2 ani vaccinurile prin spray nazal continind virusi de virulenta redusa si vaccinurile injectabile continind virusi morti previn intre 59 si 82 % din imbolnaviri. Prevenirea altor boli asemanatoare gripei a fost de numai 33-36 %. La copiii sub 2 ani eficienta vaccinurilor de tip inactiv a fost similara cu efectul placebo. Efectele asupra sanatatii ale utilizarii vaccinurilor au fost imposibil de analizat deoarece studiile nu contin suficienta informatie si lipsesc standardizarile necesare pentru putina informatie prezenta. Un raport publicat in 2008 a aratat ca vaccinarea anti-gripala a copiilor de virsta mica nu reduce numarul vizitelor la doctor sau la spital cauzate de gripa.Pe de alta parte un studiu pe 800 copii suferind de astm a aratat ca cei care au fost vaccinati anti-gripal au efectuat un numar ridicat de vizite la doctor si la camera de urgenta datorita problemelor cauzate de astm. Acest studiu a fost confirmat de un raport din 2009 care arata ca copii cu astm care au fost vaccinati cu FluMist au prezentat un risc de 3 ori mai mare de spitalizare.Vaccinurile de gripa sunt la fel de nefolositoare pentru adulti si batrini, dand protectie redusa sau deloc impotriva unei game de imbolnaviri, inclusiv a pneumoniei. Virusul gripei se modifica rapid – chiar si fara ajutorul ingineriei genetice si in special cu ajutorul unei industrii zootehnice intensive – iar vaccinul tinteste tulpini specifice. De asemenea, vaccinarea anti-gripala nu asigura protectie permanenta si trebuie repetata anual; vaccinurile sunt dificil de produs in masa iar unele tulpini nu cresc deloc in laborator.

1204941_h1n1_swine_flu_vaccine.jpg

Adjuvanti toxici in vaccinurile anti-gripale

Vaccinurile in sine pot fi periculoase, in special vaccinurile din germeni atenuati sau noile vaccinuri recombinate din acizi nucleici (10), acestea avand potential de a genera tulpini virulente prin recombinare, acizii nucleici recombinati putand cauza boli autoimune.O sursa majora de toxicitate a vaccinurilor antigripale o constituie adjuvantii, substante care au menirea sa amplifice imunogenicitatea vaccinurilor. Literatura de specialitate dedicata toxicitatii adjuvantilor este foarte vasta. Cele mai mlte vaccinuri au un continut periculos de mare de mercur sub forma de thimerosal (un conservant letal) de 50 de ori mai toxic decit mercurul insusi. O doza destul de mare poate cauza disfunctii pe termen lung la nivel imunologic, senzorial, neurologic, motor si comportamental.Otravirea cu mercur duce la autism, sindrom de atentie deficitara, scleroza multipla, deficiente de vorbire si limbaj.Institutul de Medicina a aratat ca sugarii, copiii si femeile insarcinate nu trebuie injectate cu thimseoral, dar cu toate acestea cele mai multe vaccinuri contin 25 de micrograme din aceasta substanta. Un alt adjuvant comun pentru vaccinuri este hidroxidul de aluminiu care cauzeaza alergie, soc anafilactic (…). La pisici acesta cauzeaza fibrosarcom (o forma de cancer) la nivelul injectarii cu vaccin. Numerosi adjuvanti noi nu sunt mai buni, dimpotriva, ar putea fi mai rai. Conform unei noi recenzii a publicatiilor stiintifice si farmaceutice, cei mai multi adjuvanti noi incluzind MF59, ISCOMS, OS21, AS02 si AS04 sunt (…) mai toxici decit hidroxidul de aluminiu.

y209158735702448.jpg

Statutul curent al vaccinului anti-gripa porcina

Cinci companii la nivel global au contracte pentru a produce vaccinul.  Baxter International, GlaxoSmithKline, Novartis, Sanofis-Aventis si AstroZeneca (16). Cu toate ca situatia a fost deja impinsa dincolo de orice limita, exista intentia de a produce doze tot mai mici de vaccinuri cu ajutorul unei serii de noi adjuvanti (17), totul petrecindu-se cu “binecuvintarea” OMS (vezi mai jos).Vaccinurile de gripa sunt produse traditional din virusi non-virulenti (atenuati sau slabiti) (vezi descrierea virusului in chenar).  Pentru ca vaccinurile sa fie eficiente trebuie sa contina virusul care afecteaza populatia, dar in forma non-virulenta. Vaccinul actioneaza prin faptul ca sistemul imun este activat prin expunerea la forma non-virulenta (ne-patogena) a virusului si ca urmare produce anticorpi care protejeaza organismul de forma patogena a virusului.Producerea de virusi ne-patogeni implica mai intii identificarea si producerea a doua proteine care intra in alcatuirea suprafatei virusului: hemaglutinina (H) si neuraminidaza (N), care proteine determina virulenta tulpinii virale si abilitatea sa de a se raspindi.

Virusul gripalExista 3 tipuri de virusi gripali: A, B si C. Virusul de tip A este cel care cauza majoritatea imbolnavirilor la om pasari si mamifere. Genomul sau contine 8 segmente de ARN codificind 11 proteine. Virusii sunt clasificati pe subtipuri pe baza celor 2 glicoproteine majore de suprafata: hemaglutinina (H) si neuraminidaza (N) (18). Prin segmentarea genomului, virusul are capacitatea de a-si rearanja segmentele genomice si de a se recombina ca urmare crescind rata de evolutie si generare de noi tulpini. Recombinarea este utilizata larg in laborator in procesul crearii de noi vaccinuri. Pina la ora actuala au fost identificate 16 subtipuri H si 9 subtipuri N care in circula la pasari sub forma a numeroase combinatii (19).

Virusii sursa sunt utilizati pentru producerea pe scara larga a tulpinilor virale non-virulente. Virusii sursa au fost aprobati de OMS si de catre Administratia SUA pentru Alimente si Medicamente.Metoda principala de producere a virsusilor sursa este recombinarea (vezi chenar). Oua de gaina fertilizate sunt injectate cu tulpini virale non-patogene standard care se dezvolta bine pe oua. Totodata ouale se injecteaza cu tulpina patogena care prezinta genele pentru proteinele H sau N care se doresc sa se introduca in vaccinuri.Cele doua tulpini virale se multiplica si segmentele lor genomice (8 segmente/tulpina) se rearanjeaza rezultind 256 combinatii posibile. Virusii recombinati sunt selectionati si sunt alese tulpinile care contin cele 6 segmente de genom care permit virusului sa se dezvolte pe oua si care totodata contin genele pentru proteinele H sau N ale virusului patogen (virus care circula in populatie). Virusul sursa astfel obtinut este apoi injectat in milioane de oua pentru productia de masa a vaccinului. Metoda convetionala descrisa mai sus necesita una sau doua luni pentru productia de vaccin (20).Culturile de celule ar putea eventual inlocui ouale de gaina. Baxter International detine un patent de producere a virusului patogen in culturi de celule. Virusul este apoi colectat si inactivat cu formaldehida, raze ultraviolete si detergent (21).Baxter a produs un vaccin continind virusul intreg H5N1 utilizind linii celulare Vero derivate din maimuta africana verde si au desfasurat fazele 1 si 2 ale testelor clinice cu si fara hidroxid de aluminiu (22, 23). S-a observat ca adjuvantul toxic nu determina cresterea numarului anticorpilor impotriva tulpinii virale. Baxter a consimtit sa livreze vaccin H1N1 la sfirsitul lui iulie si inceputul lui august 2009 dar detaliile despre modul de productie ale vaccinului nu au fost date publicitatii (16).In decembrie o filiala Baxter din Austria a trimis spre testare vaccinul uman anti-gripal contaminat cu tulpina letala virala H5N1 de gripa aviara in 18 tari incluzind Cehia, unde testarile s-au soldat cu moartea animalelor de laborator utilizate (24). Ziarele cehe au ridicat problema daca nu cumva firma Baxter a incercat in mod deliberat sa stirneasca o pandemie.Novartis, o alta mare firma de farmaceutice, a anuntat in 13 iunie ca a produs vaccin impotriva gripei porcine utilizind tot tehnologia bazata pe culturi de celule si adjuvantul MF59. Acest adjuvant este de natura uleioasa si contine Tween80, Span85 si squalena (25). Studiile efectuate pe soareci au aratat ca adjuvantii uleiosi induc probleme motorii si paralizie. Squalena induce artrita severa la soarecii de laborator iar in cazul subiectilor umani s-a constatat ca administrarea de squalena intre 10 si 20 ppm (parti pe miliard) duce la probleme grave ale sistemului imunitar si aparitia de maladii autoimune (26). Novartis a provocat un scandal de presa in 2008 ca urmare a testelor clinice cu vaccinul H5N1 desfasurate in Polonia.Testarea a constat in administrarea vaccinului la 350 persoane fara adapost de catre asistente medicale si medici polonezi, fapt care a dus la moartea a 21 dintre cei testati si la aducerea personalului medical in instanta de catre politia poloneza (2, 28).“fusese testat fara probleme pe 3500 de alte persoane”.Vaccinul de la GlaxoSmithKline va fi produs din antigeni ai recent izolatei tulpini gripale si va contine adjuvantul AS03 care a fost aprobat de UE impreuna cu vaccinul anti-gripa aviara H5N1 in 2008. Conform Raportului European Public de Evaluare (30) AS03 contine squalena (10.68 miligrame), DL-alfa-tocoferol (11.86 miligrame) si polisorbat 80 (4.85 miligrame). Vaccinul H5N1 contine de asemenea 5 miligrame thiomersal (derivat de mercur), polisorbat 80, octoxynol 10 si diferite saruri anorganice. Compania promoveaza agresiv diferite sisteme de adjuvanti pe post de “adjuvanti avantajosi” pentru a reduce doza de vaccin (31). Un raport recent al OMS asupra principalilor producatori de vaccinuri a concluzionat ca in cel mai bun caz se pot produce 4.9 miliarde doze de vaccin H1N1 anual asumindu-se cea mai economica dozare (aceasta include utilizarea de adjuvanti toxici selectati de fiecare producator) precum si utilizarea la maximum a capacitatilor de productie.Directorul general al OMS, Dr. Margaret Chan si secretarul general al Natiunilor Unite dl. Ban Ki-moon, s-au intilnit cu oficiali ai companiilor producatoare de vaccin in 19 mai si le-au cerut acestora sa rezerve o parte din capacitatea de productie pentru tarile sarace care altfel vor avea un acces redus la vaccin in cazul unei pandemii (32).Ultima vaccinare in masa in SUA a fost un dezastru.In 1976 s-au inregistrat citeva cazuri de gripa porcina in rindurile soldatilor de la Fort Dix, New Jersey si numai unul dintre ei a decedat cel mai probabil din cauza eforturilor fizice prea mari decit din cauza gripei (7). Aceasta a dus la lansarea unei vaccinari in masa a 40 milioane persoane impotriva unei pandemii care nu s-a materializat. Mii de oameni au cerut despagubiri pentru leziunile cauzate de vaccinare. Cel putin 25 de oameni au murit si 500 au paralizat (33, 34). Novartis a pretins la vremea respectiva ca decesele nu au fost determinate de vaccin (29) care au spus tot ei

mandatory_swine_flu_vaccine.jpg

Simptomele de gripa porcina sunt cel mult moderate

In iulie 2009 au fost inregistrate 40617 cazuri de gripa in SUA din care 319 decese, ceea ce inseamna o mortalitate de 0.8 % (35), desi se pare ca rata mortalitatii a fost de fapt mult mai redusa. Expertii estimeaza ca de fapt numai unul din 20 cazuri de gripa sunt raportate (36).Marea Britanie e cea mai afectata tara a Europei si presa a raportat zilnic despre pandemie in iulie. O noua linie telefonica de ajutor a fost deschisa in 23 iulie. Acolo oamenii pot primi sfaturi si chiar tamiflu fara sa fie consultati de medici. In saptamina deschiderii liniei  s-a ajuns la cifra de imbolnaviri record de 100000 cu un total de 30 decese (37) ceea ce inseamna o mortalitate de 0.03 % (probabil o rata a mortalitatii mai apropiata de realitate).Sir Liam Donaldson a dat dispozitii sa se faca pregatiri pentru 65000 posibile decese, cite 350 pe zi in perioada de virf a pandemiei (38). Nu exista planuri de vaccinare in masa in Marea Britanie, dar guvernul a data comanda pentru 195 milioane doze de vaccin de la GlaxoSmithKline (GSK). Vaccinul pe care GSK il produce va fi testat pe un numar redus de persoane, in timp ce, conform rapoartelor, compania cauta sa “cantareasca pericolul pandemiei fata de riscurile unui vaccin potential periculos”. Acest fapt a fost caracterizat ca riscant de prof.  Hugh Pennington, un microbiolog pensionat de la Universitatea Aberdeen, Scotia. “Prin limitarea testelor clinice, Glaxo risca sa nu calibreze doza de vaccin in mod optim si aceasta ar duce la o vaccinare care nu numai ca nu protejeaza populatia ba, mai rau, ii pune sanatatea in pericol” a aratat Pennington.Pennington a aratat de asemenea ca, abilitatea vaccinului de a declansa un raspuns imun al organismului e cruciala dar ca aceasta implica o testare aprofundata care sa determine doza optima de vaccin si totodata sa arate daca un adjuvant este intr-adevar necesar pentru sporirea efectului imun. (Dupa cum stim GSK promoveaza o noua generatie de adjuvanti toxici). Domnia sa s-a referit si la incidentul de la Fort Dix din 1976 (vezi mai sus).Franta a comandat vaccinuri de la Sanofi, GSK si Novartis dar nu vede niciun motiv pentru care ar trebui scurtata durata testelor clinice (16). Compania farmaceutica franceza Sanofi-Aventis isi dezvolta propriul vaccin impotriva gripei porcine pe care il va testa la inceputul lui august. Se estimeaza ca va fi nevoie de 2 luni si jumatate de testari pentru ca sa se obtina un vaccin “eficient si sigur” dupa cum arata Albert Garcia purtatorul de cuvint al companiei care a mai declarat ca “vaccinul va fi gata in noiembrie sau decembrie”.Baxter in schimb va incepe testarile clinice in august.Glaxo a declarat ca e pe cale sa produca o masca de fata antivirala pentru a preveni infectia si ca totodata a crescut productia medicamentului Relenza pentru bolnavii suferind deja de gripa porcina.Exista in mod clar moduri mai eficiente de a combate pandemia decit vaccinarea in masa: deasa spalare a miinilor, suflarea nasului in batiste de unica folosinta, evitarea aglomerarilor, aminarea deschiderii scolilor – toate recomandate si de guverne – si am adauga dieta sanatoasa, exercitiul fizic, vitamina D in cantitate suficienta pentru a stimula imunitatea (10)”.

270409flu2.jpg

(nu se termina aici postarea! vezi mai jos, dupa referinte!)

Referinte1. New details on virus’s promiscuous past”, Jon Cohen, ScienceScience 2009, 325, 197-201.3. Virologist to make his case for lab origin of swine flu”, Peter Duveen, Opednews.com, 4 July 2009, http://www.opednews.com/articles/Virologist-to-make-his-cas-by-Peter-Duveen-090630-103.html4. Is swine flu a biological weapon?”, Paul Joseph Watson, PrisonPlanet.com 27 April 2009, http://www.prisonplanet.com/is-swine-flu-a-biological-weapon.htm5. CDC confirms ties to virus first discovered in U.S. pig factories” Michael Greger, 3 May 2009, http://www.hsus.org/farm/news/ournews/swine_flu_virus_origin_1998_042909.html6. ”Swine flu vaccine should not be given to children in schools”, Barbara Loe Fisher, National Vaccine Information Center, 22 July 2009,http://www.nvic.org/NVIC-Vaccine-News/July-2009/Swine-Flu-Vaccine-Should-Not-Be-Given-to-Children.aspx7. ”Now legal immunity for swine flu vaccine makers” F, William Engdahl,  Global Research 20 July 2009, http://www.globalresearch.ca/index.php?context=va&aid=144538. Swine flu pandemic now ‘unstoppable’: WHO official”, Agence France-Presse 13 July 2009, Calgary Herald, http://www.calgaryherald.com/Swine+pandemic+unstoppable+official/1788693/story.html9. What are the dangers of mandatory swine flu vaccination? Dr. Mercola, June 2009, http://blogs.mercola.com/sites/vitalvotes/archive/2009/07/15/What-are-the-Dangers-of-MandatoryMandatory-Swine-Flu-Vaccination.aspx10. Ho MW. How to stop bir flu instead of the vaccine-antiviral model. Science in Society 35. 40-42, 2007.11. Jefferson T, Rivett A, Harnden A, DiPietrantoni C, and Demicheli V. Vaccines for preventing influenza in healthy children (Review). Cochrane Database Systematic Review 23 April 2009, http://mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004879/pdf_fs.html12. Szilagyi PG, Fairbrother G, Griffin MR et al. Influenza vaccine effectiveness among children 6 to 59 months of age during 2 influenza seasons: a case-cohort study. Arch Pediatr Adolesc Med 2008, 162, 943-51. http://www.ncbi.nlm.nih.gov/pubmed/1883864713. Christy C, Aligne C, Auinger P, Pulcino T and Weitzman M. Effectiveness of influenza vaccine for the prevention of asthma exacerbations. Arch. Dis Child 2004, 89, 734-5, http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&pubmedid=1526907114. Flu vaccination may triple risk for flu-related hospitalization in children with asthma, 25 May 2009, http://www.medscape.com/viewarticle/70323515. Petrovsky N, Heinzel S, Honda Y, Lyons AB. New-age vaccine adjuvants, friend or foe? BioPharm International 2 August 2007, http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=444996&sk=&date=&pageID=516.  ”Update: 1-Baxter can take no more H1N1 flu vaccine orders”, Bill Berkerto, 16 July 2009, Reuters.  http://www.reuters.com/article/marketsnews/idINN1644290820090716?rpc=3317. H1N1 ‘swine flu’ vaccine, postnote, May 2009, number 331, http://www.parliament.uk/documents/upload/postpn331.pdf18. Avian Influenza (Bird Flu) CDC, 18 November 2005, http://www.cdc.gov/flu/avian/gen-info/flu-viruses.htm19. Olsen B, Munster VJ, Wallensten A, Waldenstrom J, Osterhaus ADME and Fouchier RAM. Global patterns of influenza A virus in wild birds. Science 2006, 312, 384-8.20. Hood E. Environews Innovations 2006 Environmental Health Perpectives 114,A108-111.21. Kistner,O,Tauer,C, Barrett,N. Mundt,W. Method for Producing Viral Vaccines  2009 Patent application  US2009/0060950A122. Ehrlich HJ, Müller M, Oh HM, Tambyah PA, Joukhadar C, Montomoli E, Fisher D, Berezuk G, Fritsch S, Löw-Baselli A, Vartian N, Bobrovsky R, Pavlova BG, Pöllabauer EM, Kistner O, Barrett PN; Baxter H5N1 Pandemic Influenza Vaccine Clinical Study Team. A clinical trial of a whole-virus H5N1 vaccine derived from cell culture. N Engl J Med. 2008 Jun 12;358(24):2573-84.23. Ketel.W,Dekker,C,Mink,C,Campbell,J,Edwards,K,Patel,S,Ho,D,Talbot,H,Guo,K,Noah,D,Hill,H.Safety and immunogenicity of inactivated, Vero cell culture-derived whole virus influenza A/H5N1 vaccine given alone or with aluminum hydroxide adjuvant in healthy adults Vaccine 2009 in press doi:10.1016/j.vaccine.2009.03.01524.  ”Bird flu mix-up could have spelled disaster”, NewScientist 6 March 2009, http://www.newscientist.com/article/mg20126983.40025. Kenney RT and Edelman R. Survey of human-use adjuvants. Expert Review of Vaccines April 2003; 2(2):167-88, http://www.ncbi.nlm.nih.gov/pubmed/12899569?ordinalpos=5&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum26. “Vaccines may be linked to Gulf War Syndrome”, Chiroweb.com, June 12, 2000, http://www.chiroweb.com/mpacms/dc/article.php?id=3173027. “Homeless people die after bird flu vaccine trial in Poland”, Mathew Day, Telegraph, 2 July 2008, http://www.telegraph.co.uk/news/worldnews/europe/poland/2235676/Homeless-people-die-after-bird-flu-vaccine-trial-in-Poland.html28. “Homeless people die after trials of bird-flu vaccine”, 10 July 2008, Pharmaceutical Portal for Poland, http://www.pharmapoland.com/next.php?id=6240929. “Polish industry not dented by deaths”, Emma Dorey, Entrepreneur, 21 July 2008, http://www.entrepreneur.com/tradejournals/article/181991358.html30. Pandermrix = European Public Assessment Report [EMEA] 27 September 2009, http://www.emea.europa.eu/humandocs/Humans/EPAR/pandemrix/pandemrix.htm31. Vaccine adjuvant system technology background information. GlaxoSmithKline, accessed 25 July 2009, http://www.gsk.com/media/flu/flu-adjuvant.pdf32. Collin N, de Radiguès X, Kieny MP; the World Health Organization H1N1 Vaccine Task Force.New influenza A(H1N1) vaccine: How ready are we for large-scale production? Vaccine. 2009 Jun 26 in press doi:10.1016/j.vaccine.2009.06.03433. 1976 swine flu outbreak, Wikipedia, 22 July 2009, http://en.wikipedia.org/wiki/1976_swine_flu_outbreak34. Haber P, Sejvar J, Mikaeloff Y and DeStefano F. Vaccine and Guilaain-Barre syndrome. Drug Saf 2009, 32, 309-23.35. 2009 flu pandemic in the United States”, Wikipdeia, 22 July 2009, http://en.wikipedia.org/wiki/2009_flu_pandemic_in_the_United_States36. 2009 flu pandemic, Wikipedia, http://en.wikipedia.org/wiki/2009_flu_pandemic37. “Swine flu website overwhelmed by demand as new cases double in a week”, Owen Bowcott and Severin Carrell, The Guardian, 23 July 2009, http://www.guardian.co.uk/world/2009/jul/23/swine-flu-website-overwhelmed38. “Swine flu: medical chief orders NHS to prepare for 65 000 deaths – with a toll of as many as 350 a day”, Daniel Martin, The Daily Mail, 17 July 2009,  T, http://www.dailymail.co.uk/news/article-1200012/Swine-flu-Every-child-16-vaccinated–when.html39.  ”Glaxo to limit tests of flu vaccine, citing urgency”, Jason Gale and Trista Kelley, Bloomberg Press, 22 July 2009, http://www.bloomberg.com/apps/news?pid=20601102&sid=apkg_4J.PCEw 2009, 324, 1127.2. Garten RJ, Davis CT,Tussell CA et al.  Antigenic and genetic charaatcteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans.

comic__swine_flu_vaccine.jpg

***

In completare la articolul tradus:

Concluziile si explicatiile colaboratoarei noastre, specialista in biologie si doctor in stiinte la o universitate din Germania, care a efectuat si traducerea:

  • OMS a modificat definitia pandemiei. Vechea definitie pentru virusul cauzator de pandemie era: un nou virus (i) care se raspindeste repede (ii) si pt. care populatia nu are imunitate (iii) de aceea determina rate de morbiditate si mortalitate ridicate (iV). Noua definitie contine numai (i) si (ii). Sursa: ‘A Whole Industry Is Waiting For A Pandemic’ http://www.spiegel.de/international/world/0,1518,637119,00.html
  • Pandemia este clar promovata in scop de cistiguri financiare enorme si promovare de cariere spectaculoase (aceeasi sursa).
  • Vaccinurile vor contine adjuvanti care au rolul de a reduce cantitatea de virus omorit sau atenuat si de a stimula imunitatea organismului, dupa cum deja stiti. In acest fel se face economie la cantitatea de material viral care trebuie introdus intr-o doza. Nu se stie conform carui mecanism actioneaza aceste adjuvante dupa cum indica chiar acest articol despre actiunea adjuvantelor (vezi “summary” la sfirsitul articolului: New – Age Vaccine adjuvants: Friend or Foe? http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=444996&pageID=1&sk=&date=. Este practic un studiu care confirma cele afirmate in articolul tradus (de mai sus, n.n.). Ce mi se pare culmea culmilor e ca se folosesc ca adjuvante substante despre care nu se stie exact conform carui mecanism actioneaza ca adjuvant!
  • Numeroase surse avertizeaza ca adjuvantele sunt toxice (vezi sursa New – Age Vaccine adjuvants: Friend or Foe?un studiu intreg care arata ca in unele cazuri adjuvantele pot avea reactii adverse periculoase). Vezi si lista de mai jos.
  • Articolele despre toxicitatea adjuvantelor si faptul ca pot produce tulburari grave (autism, maladii autoimune etc.):

Vaccine Adjuvant Linked to Autism and Cellular Damage – http://www.americanchronicle.com/articles/view/111643Swine Flu Shot May Rely on Emergency Use of Additiveshttp://www.bloomberg.com/apps/news?pid=20601103&sid=a_xObcaSxF2oFLU SHOTS AND THE NEW ADJUVANTS: BEWARE!http://www.newswithviews.com/Tenpenny/sherri6.htmSqualene: The Swine Flu Vaccine’s Dirty Little Secret Exposedhttp://familycarewellness.blogspot.com/2009/08/1-squalene-swine-flu-vaccines-dirty.html

  • Presa germana (main-stream) nu se sfieste sa arate ca vaccinarea prevazuta in toamna va costa enorm de mult ( in jur de 1 miliar euro ) si ca daca se vaccineaza dupa cum se prevede la ora actuala 25 milioane persoane asta ar putea insemna 250000 oameni care sa sufere de pe urma efectelor adverse vaccinurilor.Mai mult, sunt voci care denunta vaccinarea ca pe un experiment in masa pe pielea populatiei germane. Sursa: “Großversuch an der deutschen Bevölkerung” http://www.spiegel.de/wissenschaft/mensch/0,1518,639729,00.html
  • Nu in ultimul rind: producerea de vaccin folosind linii celulare (asa cum arata si traducerea) provenind de la diverse animale este considerata de catre unii o idee periculoasa. Daca linia respectiva e contaminata intr-un fel sau in altul (chimic, patogen etc) atunci contaminarea ajunge in vaccin si de aici la populatie. Liniile celulare folosite in laboratoare sunt mentinute in viata cu ser bovin. Daca animalele de la care provine serul sunt infectate de plida atunci infectia ajunge la beneficiarii vaccinurilor. Sigur ca toate big pharma urla la ora actuala ca din gura de sarpe acompaniate de OMS ca nu vor face compromisuri cu calitatea vaccinurilor bla-bla-bla… ca totul e safe etc… asa de safe ca probabil va amintiti incidentele cu vaccinurile infectate cu gripa aviara trimise de Baxter in Cehia si scandalul care a urmat (se mentioneaza si in traducere).

In concluzie, vaccinarea are sens in cazul in care e vorba de un germen patogen care nu se modifica precum un virus si numai daca vaccinul si-a dovedit eficacitatea de-a lungul timpului.Toata campania asta hei-rupista de vaccinare mi se pare in acest moment mai mult decit suspecta. Este foarte probabil sa existe o agenda ascunsa, pe langa scopul foarte clar al obtinerii unui profit cit mai mare.Orice om cu picioarele pe pamint ar trebui sa se refuze o vaccinare accelerata impotriva unui virus de intensitatea celui actual in conditiile in care virusul se va modifica oricum iar vaccinurile vor contine cel mai probabil adjuvanti toxici.Plus ca in Romania vaccinurile vor fi, se spune, produse de Institutul Cantacuzino care prevede sa produca 5 milioane de doze pina in noiembrie.  Si in cazul vaccinurilor produse de Cantacuzino se pune aceeasi problema ca si in cazul celor produse de big pharma [marile companii farmaceutice internationale, n.n.]: adjuvanti, perioada de testare, etc.

***

Explicatii “tehnice” pentru mai buna intelegere a problemei:

Virusul consta din 2 parti: invelisul de suprafata care acopera un fragment de acid nucleic (materialul genetic-genomul) virusului. Materialul genetic codifica informatia pentru producerea proteinelor (caramizile) din care e alcatuita suprafata virusului. Aceste proteine (amintite si in articol, vezi chenar) sunt cele care determina virulenta si capacitatea virusului de a se raspindi.Materialul genetic are capacitatea de a se recombina prin segmentarea materialului genetic si rearanjarea segmentelor, la acest proces putind sa participe una sau mai multe tulpini virale daca acestea se “intilnesc”. Prin rearanjarea (sau recombinarea) materialului genetic virusul se modifica atit din punct de vedere al genomului cit si al proteinelor care alcatuiesc suprafata sa.Vaccinul contine virusi omoriti sau slabiti prin diferite procedee. Nu cred ca la inceputuri vaccinurile contineau adjuvanti, in orice caz nu contineau adjuvanti toxici. Acum insa companiile de medicamente vor sa vinda cit mai multe doze de vaccin si sa scoata un profit cit mai bun. De aceea au renuntat la metoda traditionala de a obtine vaccinul prin injectarea oualor de gaina (vezi in articolul tradus) si folosesc culturi de celule care pot fi propagate mai rapid. Dar mai ales folosesc adjuvanti. Daca in mod normal adjuvantii ar trebui sa ajute (dupa cum le e si numele) prin stimularea raspunsului imun al organismului la vaccin, ceea ce fac acum companiile farmaceutice e sa taie din doza de vaccin (de virus mort sau atenuat) si sa o inlocuiasca cu adjuvant care in multe cazuri e toxic. Adica “boteaza” vaccinul asa cum circiumarii “boteaza” vinul lungindu-l cu apa…Din lacomie s-a ajuns la situatii extreme in care adjuvantii reprezinta un procent revoltator de mare din masa dozei propriu-zise. Presupun ca se utilizeaza substante cu potential toxic pentru ca in mod natural acestea determina corpul sa se apere, sa produca anticorpi (in privinta asta ar trebui consultat un medic). Posibil ca in ecuatia actuala sa intervina si planurile malefice ale mai-marilor lumii care se tot pling de supra-populare de ani de zile. Ce e sigur e ca actuala stare de lucruri se datoreaza lacomiei marilor corporatii farmaceutice si lipsei totale de respect pentru viata a miliarde de oameni… Iar daca se ajunge sa se injecteze substante toxice pe scara globala e de presupus ca se poate ajunge chiar mai departe… tentativa de genocid. Asa ca marile coporatii ar trebui sa nu se mai ofuscheze cand sunt banuite de

5190515-u-s-panel-prepares-to-ok-swine-flu-vaccine-trials.jpg

Sursa: Război întru cuvânt